title: Sustained increase of HDL cholesterol over a 72-week period in HIV-infected patients exposed to an antiretroviral regimen including lopinavir/ritonavir.
abstract: Metabolic disorders are a major concern during antiretroviral therapy, especially for their potential to increase cardiovascular disease risk. In a multicenter, prospective study conducted in patients exposed to an antiretroviral regimen including lopinavir boosted with ritonavir, an early and sustained increase of high-density lipoprotein cholesterol was observed over a 72-week period. This increase was positively correlated with the exposure to lopinavir/ritonavir during the first 24 weeks.
authors.affiliation: Service des maladies infectieuses et tropicales, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Meynard
authors.forename: Karine
authors.initials: K
authors.lastname: Lacombe
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Poirier
authors.forename: Olivier
authors.initials: O
authors.lastname: Massot
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Lefebvre
authors.forename: Olivier
authors.initials: O
authors.lastname: Bouchaud
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Guiard-Schmidt
authors.forename: Alvaro
authors.initials: A
authors.lastname: Martinez
authors.forename: Pascale
authors.initials: P
authors.lastname: Benlian
authors.forename: Pierre-Marie
authors.initials: PM
authors.lastname: Girard
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage; D008076:Cholesterol, HDL / Q000378:metabolism*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics; D015497:HIV-1; D006801:Humans; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D011744:Pyrimidinones / Q000008:administration & dosage / Q000493:pharmacokinetics; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D019438:Ritonavir / Q000008:administration & dosage / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D008076:Cholesterol, HDL; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir; D019438:Ritonavir